Ionis rides 2026 FDA approvals as analysts cut price targets
Ionis Pharmaceuticals says 2026 FDA approvals and launch momentum will drive growth, while analysts trimmed price targets cited as Morgan Stanley, Barclays, Goldman Sachs, BMO and Canaccord.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.